Biaryl Urea Synthesis via Segmented Reaction Steps

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for preparing biaryl urea derivatives are inefficient in inhibiting IMPDH enzyme activity, which is crucial for treating IMPDH-mediated diseases.

Innovation Solution

A process involving the reaction of compounds of formula II and III under specific conditions to produce biaryl urea compounds, which effectively inhibit IMPDH enzyme activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current methods are used for preparing biaryl urea derivatives, then the preparation process can be carried out, but the efficiency in inhibiting IMPDH enzyme activity is insufficient

Engineering Contradiction:
ImproveIMPDH enzyme inhibition efficiencyVSAvoidpreparation efficiency
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent applies parameter changes by optimizing reaction conditions including temperature ranges (0-25°C for Step 1, 25-50°C for Step 2), solvent selection (dichloromethane, diethyl ether, or ethyl acetate), and reagent equivalents (1.1-2.0 equivalents of compound II or III). These parameter optimizations enable the preparation method to produce biaryl urea derivatives with improved IMPDH enzyme inhibition efficiency while maintaining practical preparation feasibility

Inventive Principle:
Principle #35Parameter changes

2Reliability

If the reaction conditions are optimized to improve IMPDH inhibition, then the therapeutic effectiveness increases, but the process complexity may increase

Engineering Contradiction:
Improvetherapeutic effectivenessVSAvoidprocess complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent segments the synthesis into two distinct steps: Step 1 involves reacting compound I with compound II in a first solvent at 0-25°C to form an intermediate, and Step 2 involves reacting the intermediate with compound III in a second solvent at 25-50°C to produce the final biaryl urea derivative. This segmentation allows optimization of each step's conditions independently, achieving high therapeutic effectiveness while maintaining manageable process complexity through clear stage separation

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent uses an intermediate compound formed in Step 1 as a mediator between the starting materials and final product. This intermediate allows the reaction to proceed through optimized stages, enabling high IMPDH inhibition efficiency while simplifying the overall process control compared to a single-step reaction

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The process yields biaryl urea compounds that efficiently inhibit IMPDH enzyme activity, providing therapeutic potential for treating IMPDH-mediated diseases.

Implementation Method 1

reacting a compound of formula II or a synthetically acceptable analog or derivative thereof with a compound of formula III or a synthetically acceptable analog or derivative thereof, under suitable conditions

Methodology Applied
Scientific EffectChemical reaction: Chemical Bonding

Data Source

PatentUS7777048B2Processes for preparing biaryl ureas and analogs thereof
Publication Date: 2010.08.17 VERTEX PHARMACEUTICALS INC
  • US7777048B2 patent drawing
  • US7777048B2 patent drawing
  • US7777048B2 patent drawing

AI summary

The present invention relates to processes for preparing biaryl ureas derivatives and analogs thereof. The invention also provides compounds useful as intermediates in the processes of the present invention. The process is useful for preparing compounds that inhibit IMPDH.